There are no files associated with this item.
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.citation.endPage | 948 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 935 | - |
dc.citation.title | EMBO MOLECULAR MEDICINE | - |
dc.citation.volume | 5 | - |
dc.contributor.author | Park, Jiyoung | - |
dc.contributor.author | Morley, Thomas S. | - |
dc.contributor.author | Scherer, Philipp E. | - |
dc.date.accessioned | 2023-12-22T03:45:31Z | - |
dc.date.available | 2023-12-22T03:45:31Z | - |
dc.date.created | 2014-10-13 | - |
dc.date.issued | 2013-06 | - |
dc.description.abstract | Endotrophin is a cleavage product of collagenVIα3 (COL6A3). Here, we explore the relationship between thiazolidinediones (TZDs), endotrophin and cisplatin resistance in the context of a mammary tumour model. COL6A3 levels are increased in response to cisplatin exposure in tumours. Endotrophin, in turn, causes cisplatin resistance. The effects of endotrophin can be bypassed, either through use of COL6 null (COL6-/-) mice or by administering TZDs in wild-type mice (leading to a downregulation of endotrophin). Both approaches sensitize tumours to cisplatin through the suppression of endotrophin-induced epithelial-mesenchymal transition. The beneficial effects of TZDs on cisplatin sensitivity are diminished in COL6-/- mice, whereas endotrophin+ tumours are sensitive to the TZD/cisplatin combination. Therefore, the chemosensitization obtained with TZDs is achieved through a downregulation of endotrophin. Treatment with an endotrophin neutralizing antibody in combination with cisplatin completely inhibits tumour growth of tumour allografts. Combined, our data suggest that endotrophin levels are a strong prognostic marker for the effectiveness of the combination therapy of TZDs with cisplatin, and neutralization of endotrophin activity dramatically improves the therapeutic response to combination therapy. | - |
dc.identifier.bibliographicCitation | EMBO MOLECULAR MEDICINE, v.5, no.6, pp.935 - 948 | - |
dc.identifier.doi | 10.1002/emmm.201202006 | - |
dc.identifier.issn | 1757-4676 | - |
dc.identifier.scopusid | 2-s2.0-84878701268 | - |
dc.identifier.uri | https://scholarworks.unist.ac.kr/handle/201301/7159 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84878701268 | - |
dc.identifier.wosid | 000319873600014 | - |
dc.language | 영어 | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours | - |
dc.type | Article | - |
dc.description.isOpenAccess | FALSE | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | cisplatin | - |
dc.subject.keywordAuthor | collagen VI | - |
dc.subject.keywordAuthor | endotrophin | - |
dc.subject.keywordAuthor | thiazolidinediones | - |
dc.subject.keywordPlus | ACTIVATED RECEPTOR-GAMMA | - |
dc.subject.keywordPlus | LUNG-CANCER CELLS | - |
dc.subject.keywordPlus | PPAR-GAMMA | - |
dc.subject.keywordPlus | EXTRACELLULAR-MATRIX | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | MESENCHYMAL TRANSITION | - |
dc.subject.keywordPlus | PANCREATIC-CANCER | - |
dc.subject.keywordPlus | DRUG-RESISTANCE | - |
dc.subject.keywordPlus | OVARIAN-CANCER | - |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Tel : 052-217-1404 / Email : scholarworks@unist.ac.kr
Copyright (c) 2023 by UNIST LIBRARY. All rights reserved.
ScholarWorks@UNIST was established as an OAK Project for the National Library of Korea.